10:55 AM EST, 12/12/2024 (MT Newswires) -- Revance Therapeutics' ( RVNC ) board recommended that stockholders tender their shares to Crown Laboratories, the companies said Thursday.

Crown said it launched a cash tender offer to acquire all outstanding Revance common shares for $3.10 per share in connection with Crown's proposed acquisition of Revance.

The tender offer is set to expire a minute after 11:59 pm ET on Jan. 13, 2025, Crown said.

In a regulatory filing Thursday, Revance said its board determined that the offer made by Crown's Reba Merger Sub unit is "advisable and in the best interests of Revance and its stockholders."

Revance shares were up 1.3% in recent Thursday trading.

Price: 3.08, Change: +0.04, Percent Change: +1.32